Table 8 Summary of studies in which multimodal treatment was performed without dissection of the internal mammary lymph node for patients with breast cancer and internal mammary lymph node metastases
From: Optimal radiotherapy for patients with internal mammary lymph node metastasis from breast cancer
Authors | No. of patients | Median FU (months) | Pathologic confirmation of IMN+ | Chemotherapy regimen | Median IMN RT dose, (range) | IMN recurrence | 5-year survival rates |
|---|---|---|---|---|---|---|---|
Zhang et al. (4) | 96 | 41 | 9% | AT-based (100%) | 60.0 Gy (50.0–72.0 Gy) | 11% | DFS 56%, OS 76% |
Park et al. (25)1) | 15 | 38 | 0% | T-based (73%), A-based (20%) | 50.4 Gy (50.4–55.8 Gy) | 6.7% | DFS 67%, OS 79% |
Noh et al. (26)1) | 45 | 57 | 40% | AT (54.5%), AC (29.1%) | 50.0–50.4 Gy +/− boost | 0% | DFS 66%, OS 76% |
Joo et al. (12) | 70 | 51 | 57% | T-based (94%) | 60.0 Gy (56.0–66.0 Gy) | 2.9% | DFS 72%, OS 77% |
Sachdev et al. (27) | 25 | 38 | Not reported | Not reported | 50.4 Gy (45.0–64.4 Gy) | 0% | Not reported |
Kim et al. (28) | 95 | 43 | 2% | Not reported | 50.0 Gy +/− boost (n = 12) | 3.2% | DFS 70%, OS 84% |
The present study | 84 | 58 | 48% | T-based (100%) | 62.5 Gy (50.0–66.5 Gy) | 2.4% | DFS 72%, OS 81% |